FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087643669> ?p ?o ?g. }

• W3087643669 endingPage "88.e6" @default.
• W3087643669 startingPage "88.e1" @default.
• W3087643669 abstract "Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication that occurs after hematopoietic cell transplantation (HCT). The mortality associated with untreated VOD/SOS with multiorgan dysfunction (MOD) has been reported to be >80%. The recommended dose of defibrotide is 6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms. The objective of this analysis was to evaluate the time to complete response (CR) in patients with post-HCT VOD/SOS treated with defibrotide. The time to defibrotide discontinuation due to a CR served as a surrogate for time to CR in an expanded access study (T-IND; ClinicalTrials.gov NCT00628498; n = 1000), and was analyzed separately from the time to CR data pooled from a phase 2 randomized dose-finding study (NCT00003966; n = 74 patients who received 25 mg/kg/day) and a phase 3 historically controlled study (NCT00358501; n = 102). For all studies, a CR was defined as total serum bilirubin <2 mg/dL with resolution of VOD/SOS-related MOD (renal and/or pulmonary dysfunction); the phase 2 study also required resolution of central nervous system dysfunction. In the T-IND, 390 patients discontinued treatment due to a CR and had sufficient data for analysis. The median time to discontinuation was 22 days (range, 2 to 64 days). Discontinuation due to CR occurred beyond 21 days in 235 patients (60%) and beyond 28 days in 57 patients (15%). The pooled phase 2 and 3 studies included 60 patients who achieved a CR, with a median time to CR of 24.5 days (range, 7 to 123 days). A CR was achieved beyond 21 days in 32 patients (53%) and beyond 28 days in 24 patients (40%). The Kaplan-Meier estimate of day +100 survival rate was substantially higher in patients who discontinued due to a CR compared with those who did not (92.5% versus 37.3%). Treatment-emergent adverse events occurred in 185 of 390 patients (47%) who discontinued due to a CR in the T-IND and in 55 of 60 patients (92%) who achieved a CR in the pooled phase 2 and 3 studies, and rates did not differ according to duration of treatment (≤21 days versus >21 days). Taken together, these results highlight the importance of continued defibrotide therapy until resolution of VOD/SOS signs and symptoms, as currently indicated in the approved product labels, which may occur beyond the recommended minimum of 21 days." @default.
• W3087643669 created "2020-09-25" @default.
• W3087643669 creator A5008479139 @default.
• W3087643669 creator A5043526996 @default.
• W3087643669 creator A5072449563 @default.
• W3087643669 creator A5076642923 @default.
• W3087643669 creator A5077440294 @default.
• W3087643669 creator A5079103223 @default.
• W3087643669 date "2021-01-01" @default.
• W3087643669 modified "2023-09-26" @default.
• W3087643669 title "Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation" @default.
• W3087643669 cites W1973519172 @default.
• W3087643669 cites W1993783426 @default.
• W3087643669 cites W2005419063 @default.
• W3087643669 cites W2064322221 @default.
• W3087643669 cites W2066216766 @default.
• W3087643669 cites W2087647234 @default.
• W3087643669 cites W2091082315 @default.
• W3087643669 cites W2094076572 @default.
• W3087643669 cites W2164925658 @default.
• W3087643669 cites W2295805773 @default.
• W3087643669 cites W2803440649 @default.
• W3087643669 doi "https://doi.org/10.1016/j.bbmt.2020.09.008" @default.
• W3087643669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8549529" @default.
• W3087643669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32950693" @default.
• W3087643669 hasPublicationYear "2021" @default.
• W3087643669 type Work @default.
• W3087643669 sameAs 3087643669 @default.
• W3087643669 citedByCount "4" @default.
• W3087643669 countsByYear W30876436692021 @default.
• W3087643669 countsByYear W30876436692022 @default.
• W3087643669 crossrefType "journal-article" @default.
• W3087643669 hasAuthorship W3087643669A5008479139 @default.
• W3087643669 hasAuthorship W3087643669A5043526996 @default.
• W3087643669 hasAuthorship W3087643669A5072449563 @default.
• W3087643669 hasAuthorship W3087643669A5076642923 @default.
• W3087643669 hasAuthorship W3087643669A5077440294 @default.
• W3087643669 hasAuthorship W3087643669A5079103223 @default.
• W3087643669 hasBestOaLocation W30876436691 @default.
• W3087643669 hasConcept C126322002 @default.
• W3087643669 hasConcept C141071460 @default.
• W3087643669 hasConcept C2777408962 @default.
• W3087643669 hasConcept C2777712501 @default.
• W3087643669 hasConcept C2778715236 @default.
• W3087643669 hasConcept C2780895475 @default.
• W3087643669 hasConcept C2911091166 @default.
• W3087643669 hasConcept C71924100 @default.
• W3087643669 hasConcept C81182388 @default.
• W3087643669 hasConcept C90924648 @default.
• W3087643669 hasConceptScore W3087643669C126322002 @default.
• W3087643669 hasConceptScore W3087643669C141071460 @default.
• W3087643669 hasConceptScore W3087643669C2777408962 @default.
• W3087643669 hasConceptScore W3087643669C2777712501 @default.
• W3087643669 hasConceptScore W3087643669C2778715236 @default.
• W3087643669 hasConceptScore W3087643669C2780895475 @default.
• W3087643669 hasConceptScore W3087643669C2911091166 @default.
• W3087643669 hasConceptScore W3087643669C71924100 @default.
• W3087643669 hasConceptScore W3087643669C81182388 @default.
• W3087643669 hasConceptScore W3087643669C90924648 @default.
• W3087643669 hasFunder F4320307105 @default.
• W3087643669 hasFunder F4320312570 @default.
• W3087643669 hasFunder F4320332161 @default.
• W3087643669 hasFunder F4320337351 @default.
• W3087643669 hasIssue "1" @default.
• W3087643669 hasLocation W30876436691 @default.
• W3087643669 hasLocation W30876436692 @default.
• W3087643669 hasLocation W30876436693 @default.
• W3087643669 hasLocation W30876436694 @default.
• W3087643669 hasOpenAccess W3087643669 @default.
• W3087643669 hasPrimaryLocation W30876436691 @default.
• W3087643669 hasRelatedWork W2750010053 @default.
• W3087643669 hasRelatedWork W2751030399 @default.
• W3087643669 hasRelatedWork W2786352895 @default.
• W3087643669 hasRelatedWork W2791058406 @default.
• W3087643669 hasRelatedWork W3014544491 @default.
• W3087643669 hasRelatedWork W3028999888 @default.
• W3087643669 hasRelatedWork W3087643669 @default.
• W3087643669 hasRelatedWork W4226404904 @default.
• W3087643669 hasRelatedWork W4288657936 @default.
• W3087643669 hasRelatedWork W4319263277 @default.
• W3087643669 hasVolume "27" @default.
• W3087643669 isParatext "false" @default.
• W3087643669 isRetracted "false" @default.
• W3087643669 magId "3087643669" @default.
• W3087643669 workType "article" @default.